SEARCH

SEARCH BY CITATION

References

  • Bolger G. B., Erdogan S., Jones R. E., Loughney K., Scotland G., Hoffmann R., Wilkinson I., Farrell C. and Houslay M. D. (1997) Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328, 539548.
  • Bolger G. B., McPhee I. and Houslay M. D. (1996) Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J. Biol. Chem. 271, 10651071.
  • Bolger G., Michaeli T., Martins T., St John T., Steiner B., Rodgers L., Riggs M., Wigler M. and Ferguson K. (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol. Cell Biol. 13, 65586571.
  • Bolger G. B., Rodgers L. and Riggs M. (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149, 237244.
  • Boundy V. A., Chen J. and Nestler E. J. (1998) Regulation of cAMP-dependent protein kinase subunit expression in CATH.nd SH-SY5Y cells. J. Pharmacol. Exp. Ther. 286, 10581065.
  • Conti M. and Jin S. L. (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucl. Acid Res. Mol. Biol. 63, 138.
  • Conti M., Nemoz G., Sette C. and Vicini E. (1995) Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16, 370389.
  • Duman R. S., Heninger G. R. and Nestler E. J. (1997) A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597606.
  • Engels P., Fichtel K. and Lubbert H. (1994) Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350, 291295.
  • Erdogan S. and Houslay M. D. (1997) Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem. J. 321, 165175.
  • Houslay M. D. and Milligan G. (1997) Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 22, 217224.
  • Houslay M. D., Sullivan M. and Bolger G. B. (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44, 225342.
  • Huston E., Lumb S., Russell A., Catterall C., Ross A. H., Steele M. R., Bolger G. B., Perry M. J., Owens R. J. and Houslay M. D. (1997) Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem. J. 328, 549558.
  • Iona S., Cuomo M., Bushnik T., Naro F., Sette C., Hess M., Shelton E. R. and Conti M. (1998) Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53, 2332.
  • Jin S. L., Bushnik T., Lan L. and Conti M. (1998) Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J. Biol. Chem. 273, 1967219678.
  • Lim J., Pahlke G. and Conti M. (1999) Activation of the cAMP- specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. J. Biol. Chem. 274, 1967719685.
  • Lobban M., Shakur Y., Beattie J. and Houslay M. D. (1994) Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304, 399406.
  • McPhee I., Pooley L., Lobban M., Bolger G. and Houslay M. D. (1995) Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem. J. 310, 965974.
  • Manning C. D., McLaughlin M. M., Livi G. P., Cieslinski L. B., Torphy T. J. and Barnette M. S. (1996) Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J. Pharmacol. Exp. Ther. 276, 810818.
  • Monaco L., Vicini E. and Conti M. (1994) Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J. Biol. Chem. 269, 347357.
  • Montminy M., Gonzalez G. A. and Yamamoto K. K. (1990) Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13, 184188.
  • Naro F., ZhangR. and ContiM.()Developmental regulation of unique adenosine 3′,5′-monophosphate-specific phosphodiesterase variants during rat spermatogenesis.Endocrinology137, 24642472.
  • Oki N., Takahashi S. I., Hidaka H. and Conti M. (2000) Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J. Biol. Chem. 275, 1083110837.
  • Olsen A. E. and Bolger G. B. (2000) Physical mapping and promoter structure of the murine cAMP-specific phosphodiesterase PDE4A gene. Mamm. Genome 11, 4145.
  • Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L., Huston E., Sullivan M. and Houslay M. D. (2001) Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic AMP-specific phosphodiesterase PDE4A10. Mol. Pharmacol. 59, 9961011.
  • Sette C. and Conti M.(1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem.271, 1652616534.
  • Sette C., Vicini E. and Conti M.(1994)The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem.269, 1827118274.
  • Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S. L., Campbell A. M., Beattie J., Daly C. and Houslay M. D. (1995) Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306, 801809.
  • Shaywitz A. and Greenberg M. (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821861.
  • Shieh P. B., Hu S. C., Bobb K., Timmusk T. and Ghosh A. (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20, 727740.
  • Sullivan M., Rena G., Begg F., Gordon L., Olsen A. S. and Houslay M. D. (1998) Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochem. J. 333, 693703.
  • Swinnen J. V., Joseph D. R. and Conti M. (1989) The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl Acad. Sci. USA 86, 81978201.
  • Takahashi M., Terwilliger R., Lane S., Mezes P. S., Conti M. and Duman R. S. (1999) Chronic antidepressant administration increases the expression of cAMP phosphodiesterase 4A and 4B isoforms. J. Neurosci. 19, 610618.
  • Tao X., Finkbeiner S., Arnold D. B., Shaywitz A. J. and Greenberg M. E. (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709726.
  • Thome J., Sakai N., Shin K., Steffen C., Zhang Y. J., Impey S., Storm D. and Duman R. S. (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 40304036.
  • Torphy T. J., Zhou H. L., Foley J. J., Sarau H. M., Manning C. D. and Barnette M. S. (1995) Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of β-adrenoceptor agonists. J. Biol. Chem. 270, 2359823604.
  • Verghese M. W., McConnell R. T., Lenhard J. M., Hamacher L. and Jin S. L. (1995) Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47, 11641171.
  • Vicini E. and Conti M. (1997) Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol. Endocrinol. 11, 839850.
  • Yarwood S. J., Steele M. R., Scotland G., Houslay M. D. and Bolger G. B. (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J. Biol. Chem. 274, 1490914917.
  • Ye Y., Conti M., Houslay M. D., Faroqui S. M., Chen M. and O'Donnell J. M. (1997) Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J. Neurochem. 69, 23972404.
  • Ye Y., Jackson K. and O'Donnell J. M. (2000) Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J. Neurochem. 74, 12571262.